Recent labeling changes for Vyvanse and Latuda

Recently, the federal Food and Drug Administration approved a labeling change for the Vyvanse chewable tablet (lisdexamfetamine), a stimulant indicated to treat attention‐deficit hyperactivity disorder in children ages 6 to 17 years. The new labeling states: Vyvanse chewable tablets must be chewed thoroughly before swallowing. Vyvanse capsules can be substituted with Vyvanse chewable tablets on a unit per unit/mg per mg basis (for example, 30 mg capsules for 30 mg chewable tablet). This is a new formulation. The change was issued Jan. 28.